United BioSource Corp. Expands Its European Capabilities With Key Hire

    United BioSource Corp. Expands Its European Capabilities With Key Hire

  PR Newswire

  BLUE BELL, Pennsylvania, Feb. 7, 2013

- Janine Collins, MD, Brings Risk Management and Drug Safety Experience in
Broad Range of Therapeutic Areas to European Market

BLUE BELL, Pennsylvania, Feb. 7, 2013 /PRNewswire/ -- United BioSource Corp.
(UBC), a subsidiary of Express Scripts, is expanding its industry-leading
pharmaceutical risk management services in Europe, where biopharmaceutical
clients based in Europe or with a major operating presence on the continent
can now better leverage the expertise of the market leader in the United

Janine Collins, MD, based in Geneva, Switzerland, will direct UBC's European
Risk Management division, under the leadership of Annette Stemhagen, doctor of
public health and fellow of the International Society for
Pharmacoepidemiology, a leading adviser of drug safety regulations and
programs in the United States. Dr. Collins, a graduate of St. George's
Hospital Medical School in London, has expertise in:

  *Developing European risk-management plans and risk-minimization strategies
    in response to regulatory requirements
  *Designing and implementing mandated post-authorization safety studies
  *Leading risk-management programs for two teratogenic products, Revlimid
    and Thalidomide

Sean Hart, UBC general manager & senior vice president, said, "It is vital for
providers of risk-management and pharmacovigilance services to have experience
working with the regulatory agencies in each European country and to
understand the intricacies of a global launch that includes the European
Union. Dr. Collins brings both of these to the table. A risk-management
professional based in Europe, she is the right executive to support UBC's
commitment to the region."

UBC is a market leader in North America in managing risk management and
risk-minimization programs on behalf of pharmaceutical companies.UBC
scientific experts have worked closely with the Food and Drug Administration
(FDA) to develop Risk Evaluation and Mitigation Strategies (REMS) after the
Food and Drug Administration Amendments Act of 2007 gave the FDA the authority
to require a REMS from manufacturers to ensure that the benefits of a drug or
biological product outweigh its risks. UBC currently is operating across
Europe with key offerings in periapproval and post-approval research,
pharmacovigilance, risk-management consulting and clinical-development

The addition of Dr. Collins secures UBC's place in Europe as a leader in
providing risk-management services for the European drug market, Dr. Stemhagen
said. "Dr. Collins developed her extensive experience in risk management as
these concepts were evolving in Europe. She has a strong track record of
relations with Rapporteurs, the European Medicines Agency (EMA), National
Competent Authorities, healthcare providers and patient groups."

About United BioSource Corporation

United BioSource Corporation (UBC), a wholly owned subsidiary of Express
Scripts Holding Company, is a global scientific and medical affairs
organization that partners with life science companies to make medicine and
medical products smarter for all stakeholders in the healthcare landscape. UBC
helps deliver authoritative, real-world evidence to characterize product
effectiveness, address safety risk and demonstrate value. UBC brings together
recognized scientific and industry experts, research operations professionals
and new technologies to provide innovative solutions across the product
lifecycle. Services include clinical and periapproval studies, risk management
and pharmacovigilance, product access and channel management, reimbursement
and patient assistance, nursing and adherence, and data analytics. More
information can be found at www.ubc.com .

About Express Scripts

Express Scripts (NASDAQ: ESRX) manages more than a billion prescriptions
annually for tens of millions of people. On behalf of our clients — employers,
health plans, unions and government health programs — we make the use of
prescription drugs safer and more affordable. We innovate to enhance patient
care, reduce pharmacy-related waste and increase therapy adherence. Through
Health Decision Science(SM) — our new platform for discovery and innovation
that's at the heart of creating value for patients and plan sponsors — we are
making it easier for people to make better health decisions.

Headquartered in St. Louis, Express Scripts provides integrated pharmacy
benefit management services, including network-pharmacy claims processing,
home delivery from the Express Scripts Pharmacy(SM), specialty benefit
management, benefit-design consultation, drug-utilization review, formulary
management, and medical and drug data analysis services. The company also
distributes a full range of biopharmaceutical products and provides extensive
cost-management and patient-care services.

For more information, visit www.Express-Scripts.com or follow @ExpressScripts
on Twitter.

Media Contact: Thom Gross, Sr. Manager, CommunicationsPhone: +1
314-684-6321Email: rtgross@express-scripts.com

Website: http://www.express-scripts.com
Press spacebar to pause and continue. Press esc to stop.